Methylphenidate

This page shows anti-doping rule violation data we have registered for Methylphenidate.

Number of cases in Methylphenidate Last 10 Years

Methylphenidate

Methylphenidate ranks #60 globally among prohibited substances, with 55 registered cases (0.4% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,670 verified cases. USA leads with 16 cases, while Track and field is the most affected sport (12 cases).

Cases of Methylphenidate by Sport
Track and field
12
Powerlifting
6
Cycling
6
Weightlifting
5
Tennis
2
Top Sport: Track and field

12

Track and field cases

0%

Of all violations

55

Total Methylphenidate cases
Track and field's share of Methylphenidate violations 0%
12 of 55

Track and field has the most recorded cases of Methylphenidate violations globally, with 12 registered cases — 0% of all 55 verified cases.

Cases of Methylphenidate by Country
USA
16
South Africa
6
Canada
5
Iran
4
Greece
3
Top Country: USA

16

USA cases

29.1%

Of all violations

55

Total Methylphenidate cases
USA's share of Methylphenidate violations 29.1%
16 of 55

USA leads significantly in Methylphenidate violations globally, with 16 registered cases — 29.1% of all 55 verified cases.

Global Substance Ranking

Methylphenidate ranks #60 of 358 prohibited substances in the Anti-Doping Database.

#1 Stanozolol
1,359
#2 Methandienone
833
#3 Norandrosterone
778
#4 Testosterone
758
···
#60 Methylphenidate
54
About This Ranking

This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.

Active Sanctions — Expiry Year
Gender Distribution
Male 78.2%
43 cases
Female 21.8%
12 cases
Analysis: 's gender distribution (78.2% male, 21.8% female) aligns closely with the global average. Global average: 80.2% male, 19.8% female
Average Suspension Length
22.7
months
Methylphenidate
30.1
months
Global average

The average suspension for Methylphenidate violations is 22.7 months, shorter than the global average of 30.1 months.

Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. The substance is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy. According to the Norwegian felleskatalogen.no the substance improves the activity in some parts of the brain which may be under active. The medicine can help improve attention (attention span), concentration and reduce impulsive behavior. According to swissinfo.ch non-ADHD sufferers also account for the increase in Ritalin consumption. Students use it as a stimulant because they are convinced that it helps them get through intense periods of study. Sources: drugs.com, swissinfo.ch and felleskatalogen.no

If you use this data, please credit The Anti-Doping Database

The intelligence tool for anti-doping professionals

Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.

 

As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:

  • Complete athlete and sanction details
    • Identity, ban periods, substances used, test type, violation information and more.
  • Verified documents and case materials
    • Access sanction decisions, PDFs and official sources when available.
  • Advanced insights and historical trends
    • Statistics across sports, countries, substances and year-by-year comparisons — for proactive planning, not just post-case analysis.

The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.